Diastolic heart failure is defined clinically when signs and symptoms of heart failure are present in the presence of preserved left ventricular systolic function (ejection fraction >45%).

Patients with ejection fraction <40% were excluded ... placebo on the functional status of elderly patients with diastolic heart failure. [21] This was a smaller study that enrolled 74 patients ...

Heart Failure, Pathophysiology, Etiology, Reduced Ejection Fraction, Preserved Ejection Fraction, Revascularization, CABG, ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

DEAR DR. ROACH: My husband is 73 and was diagnosed with heart failure and a severely dilated left ventricle. At the time, he ...

Sci & Tech and currently in Phase III for Systolic Heart Failure. According to GlobalData, Phase III drugs for Systolic Heart Failure have a 63% phase transition success rate (PTSR) indication ...

Entresto is under clinical development by Novartis and currently in Phase III for Left Ventricular Hypertrophy.

Some of the top heart failure research looked at statins and semaglutide for heart failure with preserved ejection fraction, ...

Cardiac diastolic dysfunction (CDD), ultimately leading to heart failure with preserved ejection fraction (HFpEF), is prevalent among older individuals. Although therapeutics have made great ...

Aging is an independent risk factor for cardiovascular diseases. Cardiac diastolic dysfunction (CDD), ultimately leading to ...

“In the history of heart failure ... with reduced ejection fraction (HFrEF), left ventricular cBIN1 levels linearly correlate with organ-level ventricular remodeling such as diastolic diameter.” ...

The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...